Shots:

• The companies plan to conduct a P-II pilot study of tumor treating fields concomitant with Keytryda for 1L treatment of intrathoracic advanced/ metastatic PD-L1+ NSCLC. The study will enroll ~66 patients with its anticipated initiation in H2’20
• The 1EPs od the study will be ORR while the 2EPs include OS- PFS- PFS@6mos.- one-year survival rate- DoR- disease control rate @18wks. and safety
• Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division- inhibiting tumor growth and causing cancer cells to die and causes minimal damage to healthy cell

  Ref: PRNewswire | Image: MedPage Today